Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 3 Results

Title
Intervention Indication Therapeutic Area Year Actions
Zanubrutinib for treating marginal zone lymphoma Zanubrutinib (BGB-3111; Brukinsa) Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2022 View  |  Download
Parsaclisib for marginal zone lymphoma – relapsed or refractory Parsaclisib (INCB050465) Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2021 View  |  Download
Lenalidomide (Revlimid) + rituximab for relapsed/refractory follicular lymphoma and marginal zone lymphoma Lenalidomide (Revlimid) , Rituximab (MabThera; Rituxan; RG 105) Follicular lymphoma , Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications